1Calvert H. An overview of folate metabolism:features relevant to the action and toxicities of antifolate anticancer agents [ J ]. Semin Oncol, 1999,26 ( 2 Suppl 6 ) :3.
3Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non small-cell lung cancer previously treated with chemotherapy [ J ]. J Clin Oncol,2004,22 ( 9 ) : 1 589.
4Monnerat C, Le Chevalier T, Kelly K,et al. Phase II study of pemetrexed-gerncitabine combination in patients with advanced-stage non-small cell lung cancer [J]. Clin Cancer Res,2004,10(16) :5 439.
6Rusthoven JJ, Eisenhauer E, Butts C, et al. Multitargeted antifolate LY231514 as first-line Chemotherapy for patients with advanced non-small cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group [J]. J Clin Oncol,1999,17(4) :1 194.
7Clarke S J, Abratt R, Goedhals L, et al. Phase II trial of pemetrexed disodium ( ALIMTA, LY231514 ) in chermotherapy-naive patients with advanced non-small-cell lung cancer[J]. Ann Oncol,2002,13(5) :737.
8Scagliotti GV. Pemetrexed plus carboplatin or oxaliplatin in advanced non-small cell lung cancer [ J ]. Semin Oncol, 2005,32(Suppl) :S5.
6WHO.WHO handbook for reporting results of cancer treatment WHO offset publication No.48[M].Geneva (Switzerland):World Health Organization,1979.
7Miller AB,Hoogstraten B,Staquet M,et al.Reporting resuits of cancer treatment[J].Cancer,1981,47(1):207-214.
8James K,Eisenhaner E,Christian M,et al.Measuring response in solid tumors:unidimensional versus bidimensional measurement[J].J Natl Cancer Inst,1999,91 (6):523-528.
9Padhani AR,Ollivier L.The RECIST (response evaluation criteria in solid tumors) criteria:implications for diagnostic radiologists[J].Br J Radiol,2001,74(887):983-986.
10Therasse P,Arbuck SG,Eisenhaner EA,et al.New guidelines to evaluate the response to treatment in solid tumors.European Organization for Research and Treatment of Cancer,National Cancer Institute of the United States,National Cancer Institute of Canada[J].J Natl Cancer Inst,2000,92(3):205-216.
3Buccheri G, Torchio P, Ferrigno D. Clinical equivalence of two cy- tokeratin markers in non-small cell lung cancer: a study of tissue polypeptide antigen and cytokeratin 19 fragments [ J ]. CHEST, 2013,124(2) :622-632.
4Yang CH, Simms L, Park K, etal. Efficacy and safety of cispl- atin/pemetrexed versus cisplatin/gemcitabine as first-line treat- ment in East Asian patients with advanced non-normal cell lung cancer: results of an exploratory subgroup analysis of a phaseⅢ trial [J]. J Thorac Oncol, 2010, 5(5) :688-695.
5Paz-Ares LG, Ahug S, Vaury AT. Treatment rationale and study design for a phase Ⅲ, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care im- mediately following induction treatment with pemetrexed plus cisplatin for advanced non-squamous non-small cell lung cancer [ J ]. BMC Cancer,2010,10( 1 ) :85-92.
6Brade A, Bezjak A, MacBae R, et al. Phase I trial of radiation with concurrent and consolidation pemetrexed and cisptatin in patients with unresectable stage Ⅲ A/B non-small-cen lung cancer. [ J ]. Interna- tional Journal of Radiation Oncology, Biology, Physics ,2011,79 (5) : 1395-1401.
